Walgreens, drugmakers blame others for San Francisco's opioid crisis
Send a link to a friend
[April 27, 2022]
By Dietrich Knauth
(Reuters) - Pharmacy chain Walgreens Boots
Alliance and other defendants on Tuesday said they were not to blame for
the opioid crisis in San Francisco, and that they acted responsibly when
providing legal medications to patients in pain.
"Almost all of those prescriptions were written by good, well-meaning
doctors," Walgreens attorney Kate Swift said during opening statements
in a trial in San Francisco federal court. "It was appropriate for good
pharmacists to fill those prescriptions."
The trial, which kicked off Monday, is the first to target drug
manufacturers, distributors and pharmacies over the addictive pain
medicines.
San Francisco has accused Walgreens, Teva Pharmaceutical Industries Ltd,
AbbVie Inc's Allergan unit, and drug distributor Anda Inc, which is
owned by Teva, of creating a "public nuisance" by flooding the city with
prescription opioids and failing to prevent the drugs from being
diverted for illegal use.
A lawyer for San Francisco said during opening statements on Monday that
the entire prescription drug industry was to blame for recklessly
expanding the market for opioid drugs.
San Francisco has been hit hard by the opioid crisis, which has caused
more than 500,000 overdose deaths nationwide in the past two decades,
according to the U.S. Centers for Disease Control and Prevention. Opioid-related
health issues now account for 25% of emergency room visits at the city's
largest public hospital, according to the lawsuit.
Drugmakers Teva and Allergan said on Tuesday that they were minor
players in the crisis compared to companies like Purdue Pharma and the
wealthy Sackler family that owns the now bankrupt company.
"This crisis traces back to Purdue Pharma and the Sackler family and
their pursuit of profits," said Collie James, an attorney for Teva and
its affiliates.
[to top of second column]
|
Tablets of the opioid-based Hydrocodone at a pharmacy in Portsmouth,
Ohio, June 21, 2017. REUTERS/Bryan Woolston/File Photo
By comparison, Teva's branded opioid
drugs Actiq and Fentora, made by its Cephalon unit, were "a barely
perceptible blip on the opioid market in San Francisco," James said.
Allergan attorney Hariklia Karis made similar arguments about
Allergan's branded opioids, Kadian and Norco.
"Kadian made no difference in this market," Karis said. "Norco did
not move the market."
The members of the Sackler family that own Purdue have said that
they acted lawfully, but "regret" that its widely-prescribed
OxyContin "unexpectedly became part of an opioid crisis."
San Francisco's lawsuit, filed in 2018, initially included claims
against drugmakers Purdue Pharma LP, Johnson & Johnson and Endo
International Plc, and the three largest U.S. drug distributors -
McKesson Corp, Cardinal Health Inc and AmerisourceBergen Corp. The
city previously settled with those defendants ahead of the trial.
The lawsuit was one of more than 3,000 cases filed by state and
local governments over the U.S. opioid crisis.
J&J and the three large distributors agreed to a $26 billion
nationwide settlement of opioid claims against them, which
California and San Francisco joined. But many of the lawsuits are
proceeding against other drugmakers, distributors and pharmacies.
(Reporting by Dietrich Knauth; Editing by Noeleen Walder and Bill
Berkrot)
[© 2022 Thomson Reuters. All rights
reserved.] This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|